Discover
MDGL
Madrigal Pharmaceuticals, Inc.
434.24
1 x 466.11
1 x 466.29
bid
ask
-
19.10
4.21%
1 @ 04:00 PM
434.24 +0.00 (0.00%)
| Ytd | -25.43% | |
| 1y | 2.45% |
433.31
day range
450.77
393.61
52 week range
615.00
| Open | 450.77 | Prev Close | 453.34 | Low | 433.31 | High | 450.77 | Mkt Cap | 10.03B |
| Vol | 234.85K | Avg Vol | 297.15K | EPS | -12.85 | P/E | N/A | Forward P/E | 45.12 |
| Beta | -1.05 | Short Ratio | 10.83 | Inst. Own | 104.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 509.02 | 200-d Avg | 502.63 | 1yr Est | 685.22 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.86 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -2.68 | -1.99 | 0.69 | 25.75% |
| 2026-05-06 | 2026-03 | -3.61 | -3.25 | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | -2.57 | -2.61 | -6525.00% |
| 2025-11-04 | 2025-09 | -2.04 | -5.08 | -3.04 | -149.38% |
| 2025-08-05 | 2025-06 | -3.48 | -1.9 | 1.58 | 45.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-23 | Citigroup | Upgrade | Buy | |
| 2026-08-04 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| 2026-08-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-07-29 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-06-11 | B of A Securities | Upgrade | Neutral | Neutral |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Sale |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Sale |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-08-16 | KELLEY SHANNON T | General Counsel | 11.47K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Baker Bros. Advisors, LP | 2.14M | 930.63M | 9.28% |
| 2026-06-29 | RTW Investments LP | 1.99M | 865.74M | 8.63% |
| 2026-06-29 | Jupiter Topco LLC | 1.94M | 840.73M | 8.38% |
| 2026-06-29 | Avoro Capital Advisors LLC | 1.83M | 796.11M | 7.94% |
| 2026-06-29 | PAULSON & CO. INC. | 1.34M | 581.89M | 5.80% |
| 2026-06-29 | Blackrock Inc. | 1.20M | 521.42M | 5.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 585.00K | 254.03M | 2.53% |
| 2026-07-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 563.12K | 244.53M | 2.44% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 423.14K | 183.75M | 1.83% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 338.60K | 147.03M | 1.47% |
| 2026-09-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 270.29K | 117.37M | 1.17% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 243.68K | 105.82M | 1.05% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |